EGFR and diffuse midline glioma: Our preliminary findings on the frequent presence (> 50%) of EGFR protein expression across multiple HGG disease subgroups are encouraging for including patients with broader age groups and diverse HGG subtypes (such as anaplastic ependymoma, ATRT and diffuse midline glioma, which predominate in children) in future clinical trials for imaging and antibody treatment therapy.